The U.S. Environmental Protection Agency published its draft Sixth Contaminant Candidate List on April 2, 2026, proposing for the first time that microplastics and pharmaceuticals be formally studied as potential drinking water contaminants. The same day, the Department of Health and Human Services announced a $144 million research program targeting microplastics in the human body. Together, these actions represent the most concentrated federal push yet to understand how plastic particles and drug residues affect the water Americans drink and the bodies that consume it.
What the Draft CCL 6 Actually Contains
The draft list, known as CCL 6, includes 75 individual chemicals, four chemical groups, and nine microbes. The four chemical groups are microplastics, pharmaceuticals, per- and polyfluoroalkyl substances (PFAS), and disinfection byproducts. Inclusion on the list does not impose any regulation on water utilities. Instead, it triggers a formal research and evaluation process under the Safe Drinking Water Act, during which EPA determines whether any listed contaminant warrants a binding standard.
The addition of microplastics and pharmaceuticals as named chemical groups is what distinguishes this list from its five predecessors. Previous lists focused on individual compounds. Grouping entire categories signals that EPA views these as systemic contamination problems rather than isolated chemical hazards. A 60-day public comment period is now open, and the full regulatory process from draft list to any enforceable standard is expected to take several years.
Three Years of Federal Preparation
This draft did not appear overnight. EPA formally requested public nominations for CCL 6 contaminants in early 2023 through a Federal Register notice, opening the door for outside scientists, water utilities, and advocacy groups to flag emerging threats. Microplastics and pharmaceutical compounds were among the substances nominated during that input window, and their appearance on the final draft reflects three years of screening and prioritization work inside the agency.
Parallel to the CCL process, multiple federal agencies had already committed to coordinating on pharmaceutical contamination in water supplies. A memorandum of understanding designated MOU 225-22-015 established sustained collaboration among EPA’s Office of Water, the USDA Agricultural Research Service, the Food and Drug Administration, and the U.S. Geological Survey. That agreement framed pharmaceutical contamination as a shared responsibility requiring data exchange across agencies that regulate drugs, monitor waterways, and set drinking water standards. The CCL 6 draft now gives that interagency structure a concrete regulatory vehicle to work within.
New Screening Benchmarks for 374 Drugs
EPA also released an updated set of Human Health Benchmarks for Pharmaceuticals, known as HHB-Rx, covering 374 individual drugs. These benchmarks are not enforceable limits. They function as screening tools that help water systems and researchers identify which pharmaceuticals in a water sample deserve closer attention. Each benchmark value is derived from the lowest oral therapeutic dose listed on FDA-approved drug labels, with separate values calculated for infants and the general population.
The practical effect is that any water utility or state regulator can now compare detected pharmaceutical concentrations against a federal reference point. Before these benchmarks, there was no standardized federal yardstick for evaluating whether trace drug levels in tap water were worth investigating. The full HHB-Rx table links each benchmark to its underlying FDA label source through the DailyMed database, making the scientific basis transparent and auditable. In parallel, the U.S. Geological Survey maintains health-based screening levels for a broader set of contaminants, which utilities can use alongside the new pharmaceutical benchmarks to prioritize monitoring and treatment.
The $144 Million Microplastics Research Bet
While EPA focuses on what is in the water, HHS is now funding research into what happens after those contaminants enter the body. The STOMP program, short for Systematic Targeting of Microplastics, is a $144 million initiative run through the Advanced Research Projects Agency for Health (ARPA-H). Its stated goals are to develop reliable methods for measuring microplastics and nanoplastics inside the human body, to stratify the health risks those particles pose, and to create tools capable of removing them.
That last objective, removal from the body, is where STOMP departs from typical environmental health research. Most federal programs study exposure pathways and recommend reducing intake. STOMP is explicitly tasked with building interventions that work after exposure has already occurred. If successful, this could shift the public health conversation from prevention alone to active remediation, a distinction that matters given how pervasive microplastics have become in food, air, and water.
ARPA-H intends to fund teams that can bridge basic toxicology, materials science, and clinical innovation. Some projects are expected to concentrate on measurement technologies (ways to detect and quantify microscopic plastic fragments in blood, organs, and other tissues). Others may focus on understanding which particle sizes, shapes, and chemical additives are most harmful. A third category of work will aim at interventions, potentially including filtration-like devices, targeted binding agents, or other mechanisms to capture and clear particles from the body.
Data, Safety, and Public Reporting
Both the water-contaminant work and the microplastics program depend on accurate reporting and secure handling of health information. HHS already operates digital portals such as the Safety Reporting Portal to collect information on adverse events and product problems from researchers, clinicians, and the public. As STOMP-funded tools move from laboratory concepts toward human testing, those same reporting channels are likely to play a role in tracking side effects and performance.
At the same time, federal agencies emphasize cybersecurity and responsible disclosure when researchers uncover vulnerabilities in the systems that manage health and environmental data. HHS maintains a formal vulnerability disclosure policy that outlines how security researchers can report flaws without risking legal action. Protecting the integrity of datasets on contaminants, exposures, and health outcomes is critical if regulators are to make sound decisions about which hazards warrant stricter controls.
Why the Timeline Matters for Households
For the average household, none of these actions will change what comes out of the tap tomorrow. The CCL 6 draft must survive a 60-day comment period, then finalization, and then a separate regulatory determination process before EPA could propose any enforceable drinking water standard. That sequence is expected to stretch across several years. The pharmaceutical benchmarks are voluntary screening tools, not mandates. And STOMP is a research program, not a product rollout.
But the cumulative signal to utilities, state regulators, and researchers is unmistakable: microplastics and pharmaceuticals are now front-burner issues for federal science and policy. Water systems that already test for a wide spectrum of emerging contaminants can use the new benchmarks to refine their monitoring priorities. Academic labs and public health agencies can align their research with the questions EPA and HHS have formally put on the table, increasing the odds that new findings will feed directly into future standards or medical tools.
For households that want to act sooner, point-of-use filters certified for particle removal, careful disposal of unused medications, and support for local wastewater and drinking water upgrades remain the main options. Those individual steps, however, operate in the shadow of much larger systemic questions that only national-scale research and regulation can answer: how much of these contaminants are actually present, which forms are most dangerous, and what mix of treatment, prevention, and remediation will do the most to protect health over a lifetime.
The draft contaminant list and the microplastics research program do not resolve those questions. They do, however, mark a turning point. By formally naming microplastics and pharmaceuticals as priority concerns in both drinking water and human biology, federal agencies are committing to follow the evidence wherever it leads, even if that ultimately means redesigning treatment plants, rewriting disposal rules, or developing entirely new ways to clean up the microscopic traces of modern life that now circulate through taps and veins alike.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
